Logo image of MKD

MOLECULAR DATA INC - ADR (MKD) Stock Fundamental Analysis

NASDAQ:MKD - Nasdaq - US60852L2051 - ADR - Currency: USD

0.41  +0.01 (+2.5%)

After market: 0.421 +0.01 (+2.68%)

Fundamental Rating

1

MKD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 0 industry peers in the Internet & Direct Marketing Retail industry. MKD has a bad profitability rating. Also its financial health evaluation is rather negative. MKD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MKD has reported negative net income.
MKD Yearly Net Income VS EBIT VS OCF VS FCFMKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA -42.99%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MKD Yearly ROA, ROE, ROICMKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 1K -1K

1.3 Margins

Industry RankSector Rank
OM -4.36%
PM (TTM) -4.32%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MKD Yearly Profit, Operating, Gross MarginsMKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 0 1 -1 -2 -3 -4

More info and screens

2

2. Health

2.1 Basic Checks

MKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MKD has been increased compared to 1 year ago.
The debt/assets ratio for MKD has been reduced compared to a year ago.
MKD Yearly Shares OutstandingMKD Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 100M 200M 300M
MKD Yearly Total Debt VS Total AssetsMKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 200M 400M 600M

2.2 Solvency

MKD has an Altman-Z score of 7.26. This indicates that MKD is financially healthy and has little risk of bankruptcy at the moment.
A Debt/Equity ratio of -0.29 indicates that MKD is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -0.29
Debt/FCF N/A
Altman-Z 7.26
ROIC/WACCN/A
WACC19.71%
MKD Yearly LT Debt VS Equity VS FCFMKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 100M -100M -200M

2.3 Liquidity

A Current Ratio of 0.93 indicates that MKD may have some problems paying its short term obligations.
A Quick Ratio of 0.92 indicates that MKD may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.92
MKD Yearly Current Assets VS Current LiabilitesMKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

MKD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.10%.
MKD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -42.49%.
The Revenue has been growing by 24.07% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-51.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69%
Revenue 1Y (TTM)-42.49%
Revenue growth 3Y21.82%
Revenue growth 5Y24.07%
Sales Q2Q%-67.08%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MKD Yearly Revenue VS EstimatesMKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2B 4B 6B 8B 10B
MKD Yearly EPS VS EstimatesMKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MKD. In the last year negative earnings were reported.
Also next year MKD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MKD Price Earnings VS Forward Price EarningsMKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -3.17
MKD Per share dataMKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MKD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOLECULAR DATA INC - ADR

NASDAQ:MKD (9/6/2022, 8:13:10 PM)

After market: 0.421 +0.01 (+2.68%)

0.41

+0.01 (+2.5%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustryInternet & Direct Marketing Retail
Earnings (Last)N/A N/A
Earnings (Next)09-27 2022-09-27/bmo
Inst Owners0.09%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap159.83M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -3.17
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.78
BVpS-0.02
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -4.36%
PM (TTM) -4.32%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover9.96
Health
Industry RankSector Rank
Debt/Equity -0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.92
Altman-Z 7.26
F-Score2
WACC19.71%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69%
EPS Next Y98.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.49%
Revenue growth 3Y21.82%
Revenue growth 5Y24.07%
Sales Q2Q%-67.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A